OncRef

Clinical Trial: NCT06497556

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Hoffmann-La Roche
Information Provided By:Hoffmann-La Roche
Last Update Posted:2026-09-16

Study Overview

Brief Summary

The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).

Official Title

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Conditions

Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

Intervention / Treatment

  • Drug: Divarasib
  • Drug: Sotorasib
  • Drug: Adagrasib

Other Study ID Numbers

  • BO45217
  • 2024-510908-37-00

Start Date (Actual)

2024-09-23

Primary Completion Date (Actual)

2026-05-19

Study Completion Date (Estimated)

2029-11-30

Enrollment (Actual)

338

Study Type

Interventional

Phase

Phase 3